Suppr超能文献

皮下植入式心律转复除颤器:当前标准与未来展望。

Subcutaneous ICD: Current standards and future perspective.

作者信息

Kaya Elif, Rassaf Tienush, Wakili Reza

机构信息

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Essen, Germany.

出版信息

Int J Cardiol Heart Vasc. 2019 Aug 8;24:100409. doi: 10.1016/j.ijcha.2019.100409. eCollection 2019 Sep.

Abstract

The subcutaneous implantable cardioverter-defibrillator (S-ICD) system is an established therapy for prevention of sudden cardiac death (SCD) and an alternative to a transvenous implantable cardioverter-defibrillator (ICD) system in selected patients. Since introduction of S-ICD in 2010, the device has undergone further development. Based on the unique feature of an entirely extracardiac implantation, S-ICD is able to reduce the known common perioperative and long-term complications of conventional transvenous implanted ICD systems. Especially for patients with a complex anatomy and no option of an endovascular lead implantation, the S-ICD offers a potential alternative. Initial uncertainty existed, questioning whether this ICD approach would be reliable in detecting and terminating ventricular arrhythmias. Multiple clinical studies, however, provided evidence for an effective treatment. Based on obvious advantages compared to conventional ICD systems, the question arises whether the S-ICD should actually be the first choice in the majority of all primary prevention patients in the future. Recent data from large registries show that S-ICD indications are also expanding in secondary prevention patients. As a consequence, the S-ICD was listed in the 2015 ESC guidelines as an alternative therapeutic option with a class-IIa recommendation in patients with an ICD indication not requiring pacing for bradycardia, cardiac resynchronization therapy or anti-tachycardia pacing (ATP). In addition, the American Heart Association guidelines refer to class-I recommendation for patients with a complex anatomy and venous access problems or at a high risk for infections who need ICD therapy. Limitations with respect to the not available pacing option of S-ICD might be also overcome by a potential combination with a leadless pacemaker in the near future. This article provides an overview of recent developments of S-ICD and reviews the most recent literature and ongoing studies.

摘要

皮下植入式心律转复除颤器(S-ICD)系统是预防心脏性猝死(SCD)的既定疗法,也是特定患者经静脉植入式心律转复除颤器(ICD)系统的替代方案。自2010年S-ICD推出以来,该设备不断发展。基于完全心外植入的独特特性,S-ICD能够减少传统经静脉植入ICD系统已知的常见围手术期和长期并发症。特别是对于解剖结构复杂且无法进行血管内导线植入的患者,S-ICD提供了一种潜在的替代方案。最初存在不确定性,质疑这种ICD方法在检测和终止室性心律失常方面是否可靠。然而,多项临床研究提供了有效治疗的证据。与传统ICD系统相比,基于明显优势,未来S-ICD是否应成为大多数一级预防患者的首选这一问题随之而来。大型注册研究的最新数据表明,S-ICD在二级预防患者中的适应症也在扩大。因此,S-ICD在2015年欧洲心脏病学会(ESC)指南中被列为一种替代治疗选择,对于有ICD适应症但不需要用于心动过缓起搏、心脏再同步治疗或抗心动过速起搏(ATP)的患者,给予IIa类推荐。此外,美国心脏协会指南对解剖结构复杂、存在静脉通路问题或有高感染风险且需要ICD治疗的患者给予I类推荐。S-ICD无法进行起搏这一局限性在不久的将来也可能通过与无导线起搏器的潜在组合得以克服。本文概述了S-ICD的最新进展,并回顾了最新文献和正在进行的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ff/6700427/564614c54bcb/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验